Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 Rollover Study in Advanced Solid Tumors and Hematological Malignancies
NCT06987058Phase 2Enrolling by invitation
- Sponsor
- Ryvu Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Countries
- 2
01
Overview
A Phase 2 trial of rvu120 in solid tumor (advanced stage), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Ryvu Therapeutics. Started Dec 2025; status: enrolling by invitation.
02
Drugs
rvu120
03
Conditions
solid tumor (advanced stage)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06987058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987058.